Unit sales of AtriCure's (ATRC -3.2%) AtriClip Left Atrial Appendage Exclusion System have passed 34,000 making it the top-selling device used for eliminating the left atrial appendage (LAA) according to the company.
The LAA is a muscular pouch attached to the heart's left atrium. In patients with atrial fibrillation (AF) and other arrhythmias, blood can pool and form clots in the appendage. As many as 90% of blood clots in AF patients are formed in the LAA. These patients have a 500% greater risk of stroke than the general population.
The FDA approved AtriClip in 2010.